anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pediatric traumatic injury (i.e., injury of sudden onset and severity requiring immediate attention) is the leading cause of death and morbidity among US adolescents and are associated with mental health and health risk outcomes. Pediatric traumatic injuries are associated with medical and societal costs of $87 billion and elevates risk for a wide range of health risk consequences that affect quality of life, physical recovery, social functioning, and return to previous activities. The prevalence of PTSD and depression is high among pediatric traumatic injury patients; however, most pediatric trauma centers don't have the resources to implement models of care that address mental health following injury. Current guidelines by the American College of Surgeons (ACS) Committee on Trauma strongly recommend screening and addressing emotional recovery in traumatic injury patients. The ACS Committee on Trauma has identified this as a priority and likely will begin to mandate mental health programs in Level I and II pediatric trauma centers nationally. It is therefore critical that policy and practice is guided by the implementation and evaluation of scalable and sustainable models of care. In 2015 the investigators launched the Trauma Resilience and Recovery Program (TRRP), a scalable and sustainable, technology-enhanced, multidisciplinary stepped model of care - one of the few in the US - that provides early intervention and direct services to improve access to evidence-based mental health care after traumatic injury for children, adults and families. This model of care has been found to be feasible and acceptable to adolescent patients (ages 12-17) at each level of service. TRRP includes 3 major steps: (1) in-hospital education, brief risk reduction session, and tracking patients' emotional recovery via an automated text-messaging system, (2) conducting a 30-day screen via telephone to identify patients who are good candidates for psychological treatment, and (3) providing referral to best-practice telehealth-based or in-person assessment and treatment. The investigators partnered with three accredited Level I and II pediatric trauma centers and propose a multi-site hybrid 1 effectiveness-implementation trial with 300 adolescent (ages 12-17) traumatic injury patients to: 1) assess the extent to which TRRP promotes improvement in quality of life and emotional recovery and 2) gather preliminary data on the potential for TRRP to be implemented in other Level I trauma centers. Directly in line with NICHD's Pediatric Trauma and Critical Illness Research and Training (PTCIB) Strategic Research and Training agenda, this study will provide valuable data on the efficacy, preliminary effectiveness and potential for implementation of an innovative, cost-effective, sustainable technology-enhanced intervention designed to address the unique needs of adolescent injury patients and mitigate short- and long-term impact of injury on mental health, quality of life, and overall well-being.
MPs will be intravenously infused within 48 hours after chemotherapy. During the study period, patients can receive platelet infusion but can not receive platelet stimulating factors.
To provide fine emulsification matrices, preparation methods thereof, and cosmetics containing the fine emulsification matrices.SOLUTION: The raw material of a fine emulsification matrix comprises 1 to 2 pts.wt. of butylene glycol, 2 to 3 pts.wt. of glycerin, 0.3 to 0.4 pts.wt. of PEG-60 hydrogenated castor oil, 0.1 to 1 pt.wt. of an emulsifier with HLB value of 3 to 7, 0.3 to 0.5 pts.wt. of a synthetic fat and oil, and 0.1 to 1 pt.wt. of water, the synthetic fat and oil containing no silicone oil.EFFECT: The fine emulsification matrix of the present application can obtain a fine emulsification system having excellent stability by blending the raw materials at each blending ratio, shows excellent stability at both high and low temperatures, is not easy to cause emulsification destruction and oil-water separation. The fine emulsification matrix of the present application can improve the fat and oil solubility of the synthetic fat and oil in a lotion, optimize the fat and oil selectivity of the lotion, and improve the penetration rate of active substances in the lotion.SELECTED DRAWING: None
Chronic low-grade inflammation and neuronal deregulation are two components of a smoldering disease activity that drives the progression of disability in people with multiple sclerosis (MS). Although several therapies exist to dampen the acute inflammation that drives MS relapses, therapeutic options to halt chronic disability progression are a major unmet clinical need. The development of such therapies is hindered by our limited understanding of the neuron-intrinsic determinants of resilience or vulnerability to inflammation. In this Review, we provide a neuron-centric overview of recent advances in deciphering neuronal response patterns that drive the pathology of MS. We describe the inflammatory CNS environment that initiates neurotoxicity by imposing ion imbalance, excitotoxicity and oxidative stress, and by direct neuro-immune interactions, which collectively lead to mitochondrial dysfunction and epigenetic dysregulation. The neuronal demise is further amplified by breakdown of neuronal transport, accumulation of cytosolic proteins and activation of cell death pathways. Continuous neuronal damage perpetuates CNS inflammation by activating surrounding glia cells and by directly exerting toxicity on neighbouring neurons. Further, we explore strategies to overcome neuronal deregulation in MS and compile a selection of neuronal actuators shown to impact neurodegeneration in preclinical studies. We conclude by discussing the therapeutic potential of targeting such neuronal actuators in MS, including some that have already been tested in interventional clinical trials.
The primary goals in the management of stable coronary artery disease (CAD) are to reduce risk factors for heart attack and to control the symptoms of angina (chest pain). Ideally angina is well controlled with medications alone, but invasive procedures are a valuable option for patients with persistent angina. The amount of angina among patients with stable CAD in the outpatient setting, however, is unknown. An Australian study reported that almost 1 in 3 patients with stable angina being treated by primary care doctors had angina at least once a week, which was associated with worse quality of life. We propose to examine the burden of angina in outpatients with stable CAD who are being medically managed by cardiologists in the United States through administration of a one-time survey. The information from this study could ultimately help improve management of stable CAD and angina and illuminate potential underuse of revascularization. While cardiologists are generally expected to provide better angina control than primary care doctors, establishing the prevalence of angina among the best providers will help with a framework for interpreting symptom control among other practitioners.
Interleukin-6 (IL-6) is a cytokine generated by healthy constituents of the skin, but is also up-regulated by a wide range of skin lesions and inflammatory conditions to trigger cytopathy of skin cells. TRIM27 was identified to contribute to the functional effects of IL-6 on skin cells. However, the underlying mechanism was not clear. Lentivirus infection was used for gene overexpression or silencing. RT-PCR and Western blot were used to respectively assess mRNA and protein levels. Cell viability was assessed by CCK-8 assay. Extracellular flux analysis was used to assess the levels of oxygen consumption rate and extracellular acidification rate. Mouse back skin was treated with imiquimod to produce psoriasis-like inflammation in vivo. Histological assessment and immunohistochemistry staining were respectively applied to analyse lesioned mouse and human skin samples. IL-6-induced increased viability, glycolysis and inflammation in keratinocytes was inhibited both by a chemical methylation inhibitor and by METTL14 knockdown. Further investigation found that METTL14 induces m6A methylation of TRIM27, which is recognized by a m6A reader, IGF2BP2. Elevation of TRIM27 level and activation of IL-6/STAT3 signalling pathway were found in an in vivo psoriasis-like inflammation model, whereas inhibition m6A methylation strongly alleviated the inflammation. Finally, METTL14, TRIM27, STAT3, p-STAT3 and IL-6 expressions were all found to be increased in clinical skin samples of psoriatic patients. Our results unravelled METTL14/TRIM27/IGF2BP2 signalling axis in keratinocyte cytopathy, which plays a critical role in facilitating the activation of IL-6/STAT3 signalling pathway. Our findings should provide inspirations for the design of new therapeutics for skin inflammatory diseases including psoriasis.
There is provided an isolated and purified BNIP3 protein. There is also provided a method for inducing necrosis in cells by transfecting a cell with a BNIP3 protein. A method for inducing necrosis in cells by creating a transgene overexpressing the gene for the BNIP3 protein is also provided. A transgenic animal and progeny thereof is provided having an expression factor consisting essentially of a BNIP3 protein selected from the group consisting essentially of Seq. ID 1 and 2. Also provided is a vector for use in treating disease including BNIP3 or DN NIP and a promoter. A gene therapy having DNA encoding BNIP3 or DN NIP and a promoter, whereby said gene therapy is used to induce necrosis or inhibit necrosis is also provided.
FIELD: medicine. ^ SUBSTANCE: invention refers to experimental biology and medicine. The method involves parenteral introduction of a protein preparation. Ceruloplasmin is used as said protein preparation. Ceruloplasmin is introduced intravenously in dosage 7.5 mg/kg of animal body weight, for the total course of 3 injections every second day. ^ EFFECT: method allows intensifying anti-oxidant protection of an animal body, stimulating hemopoietic and immunological processes, and thereby providing aquatation of protective adaptive responses. ^ 1 ex
Embodiments are provided for securely messaging healthcare entities. In one scenario, a computer system receives an input from a user indicating that a message including text or other characters is to be securely transmitted to a specified healthcare entity. The message is part of a conversation between a user and the specified healthcare entity. The computer system encrypts the characters of the message using at least one encryption algorithm, so that the message is encrypted during the transfer from the user to the specified healthcare entity. The computer system then initiates transmission of the encrypted message such that the encrypted message is sent to the specified healthcare entity. Throughout the process, the encrypted message is transferred in accordance with legal regulations governing healthcare communications.
Sixty-six patients were divided into six equal groups; group 1: systemically and periodontally healthy individuals, group 2: systemically healthy individuals with periodontitis, group 3: controlled type 2 diabetes and periodontally healthy individuals, group 4: controlled type 2 diabetes and periodontitis, group 5: uncontrolled type 2 diabetes and periodontally healthy individuals, group 6: uncontrolled type 2 diabetes and periodontitis. The study was planned as a randomized, single-blind, parallel design. Periodontal clinical parameters (Silness-Löe plaque index, Löe-Silness gingival index, probing pocket depth, clinical attachment level, bleeding on probing) were recorded clinically and concentrations of visfatin, fetuin-A and sirtuin 1 in gingival crevicular fluid were assessed biochemically. After baseline examinations, periodontal treatment was completed using a nonsurgical periodontal treatment protocol completed in 24 hours. Periodontal clinical parameters and gingival crevicular fluid were recorded at baseline and 3 months after periodontal treatment. Biochemical analysis and statistical evaluation were performed.
PURPOSE:To measure simultaneously various lymphocytes with a ordinary microscope, by applying simultaneously both of microcapsules antibody of lymphocyte to antigens on the surfaces of the optically identifiable microcapsules, and sheep  erythrocyte to the lymphocytes. CONSTITUTION:Microcapsules of 1-10mu are prepared so that the color tone of core  materials is different from each other respectively. For example, the core materials  contain pigments of different color tones from a sheep erythrocyte and the outer skin  of the capsules is made of a urea resin, etc. Then the microcapsules of different color tones are sensitized with antibodies to lymphocytes (such as anti-IG antibody) which  are obtained by injection of various lymphocytes to a rabbit, etc. These plural sensitized microcapsules and sheep erythrocyte dispersion are mixed with lymphocytes  dispersion separated from a blood sample, and the lymphocytes of the rosette thus  formed are counted separately by colors under a microscope. Thus, the proportion of  various lymphocytes are measured accurately and simultaneously without requiring  separation of macrophges. The identification and measurement of lymphocytes are performed easily and with good repeatability, since the amount of the sample is less than  those of conventional and the antibody sensitized capsules are stored stably for a long  time.
The invention discloses a saliva combined lactobacillus capable of inhibiting clostridium with improved breath, belonging to the technical field of microorganisms. The saliva combined lactobacillus (Ligilactobacillus salivarius) CCFM1215 is preserved in the microorganism strain preservation center of Guangdong province at 12 months and 17 days of 2021, the preservation address is the building 5 No. 59 of the university of Mitsui No. 100 of Guangzhou City, and the preservation number is GDMCC No. 62141. The bacterium can reduce the amount of the fusobacterium nucleatum biomembrane and the amount of volatile sulfide, and has the function of improving halitosis in vivo.
To determine the correlation between the severity of chronic kidney disease (CKD) and treatment of diabetic macular edema (DME). The retrospective 2-year cohort study included eyes with DME confirmed using spectral-domain optical coherence tomography in Taipei Veterans General Hospital, Taiwan, between 2010 and 2020. All the eyes were treated with an intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) during regular follow-up around 2 years. They were categorized into 3 different groups: an estimated glomerular filtration rate ≥ 60 (mL/min per 1.73 m2) (group A), < 60 (group B), and patients undergoing hemodialysis (group C). The main outcome measures were (1) visual improvement, (2) structural improvement, and (3) the injection frequency of anti-VEGF in the different groups. In this study, 167 eyes from 120 patients were enrolled. Compared with groups B and C, the eyes in group A experienced the only significant visual improvement at month 3, month 6, and month 12 (P = 0.0001, 0.0002, 0.0013, respectively). The presence of subretinal fluid and intraretinal cysts was significantly decreased in groups A and B. In the treatment frequency analysis, the number of injections was the highest in group A and lowest in group C during the study period (P = 0.04). The severity of CKD had an impact on the DME treatment. The less severe CKD was, the greater the visual improvement that could be achieved. In addition, relatively poor renal function required a lower anti-VEGF injection frequency. The active prevention of the progression of CKD may play a key role in DME treatment.
Mechanical asphyxiation has been a common method used to commit homicide, including femicide, throughout history. A recent report by the United Nations has shed light on the issue of misidentification and concealment of gender-related killings, which makes it difficult to effectively fight against it. Forensic pathologists are frequently asked to examine cases involving suspected asphyxia to determine whether other persons have been involved. Therefore, medicolegal experts must look for signs of occlusion of the oral/nasal orifices, compression of the neck, or specific signs such as the "facie sympathique". There are situations where the physical signs are not distinctive enough to diagnose asphyxia, especially in cases where the individual has limited ability to resist external compression. In such cases, judicial autopsies should include an anatomical dissection of the neck structures through a layer-by-layer progression. It is important to search for the Amussat's sign, e.g., as part of a Forensic Clinical Anatomy approach. Additionally, individual anatomical variations, age or artefactual modifications, must be considered for the correct interpretation of findings. Microscopic examinations could aid in the diagnosis by providing additional findings, and several attempts have been made to identify unique markers of asphyxia through various laboratory techniques such as biochemistry, radiology and miRNA studies. However, no single finding or method has been identified as definitive. In the future, biomedical-legal sciences will have to rely on scientific research and the retrospective case series to provide a scientific framework on which to base their hypothesis, giving weight to evidence in the trial.
Lymphangioleiomyomatosis (LAM), a disease primarily of women of child-bearing age, is characterized by cystic lung disease and abdominal tumors (e.g., angiomyolipomas). Within the LAM patient population is a subset of patients who develop chylous ascites, chylous pleural effusions, chyluria, peripheral lymphedema, and/or lymphangioleiomyomas. Lymphangioleiomyomas are believed to result from a proliferation of abnormal smooth muscle cells within the lymphatic system, which appears to obstruct fluid outflow, leading to fluid accumulation and an increase in size. The lymphangioleiomyomas may occur anywhere along the axial lymphatic chain. In patients with LAM, they occur most frequently in the thorax, abdomen and pelvis and may give rise to a myriad of symptoms (e.g., paresthesias, palpitations, peripheral edema). In some patients, treatment of many of these symptoms, i.e., elevation of lower extremities, paracentesis, thoracentesis, diuretics, and/or surgery, has been ineffective. Previous studies with somatostatin and octreotide in other clinical settings (e.g., traumatic damage to the lymphatics) have shown a successful reduction in chylous effusions, chyluria, ascites, and peripheral lymphedema, when other therapies were less effective. This study will assess the effectiveness of octreotide in symptomatic patients with LAM, lymphangioleiomyomas and/or chylous effusions/ascites, peripheral lymphedema and chyluria. The dose of octreotide starts at 50 micrograms (ug) by the subcutaneous route twice a day. After two weeks the dose will be increased to 200 ug per day and two weeks later to 400 ug/day. Maximal dose is 400 ug twice a day.
The invention provides derived peptide IR2 of a boar derived antimicrobial peptide and its preparation method and application. Is the sequence of the derived peptide IR2 of pig derived antimicrobial peptide as SEQ? ID? shown in No.1. The present invention adopts the method that pinpoint amino acid fragment intercepts and binary amino acid sequence superposes, intercept 6 amino acid fragments of pig source PG-1 rotation angle position, and using charge residue arginine and hydrophobic amino acid isoleucine as the both sides of repeating binary sequence unit symmetrical cycle and be arranged in this corner, obtain IR1 and IR2 antibacterial peptide. The bacteriostatic activity of IR2 is better than IR1. The therapeutic index of IR2, up to 43.2, is 216 times of pig derived antimicrobial peptide PG-1. By the method, in the situation that improving antibacterial peptide bactericidal activity, greatly reduce the hemolytic activity of antibacterial peptide, improve selective between bacterial cell and mammalian cell of antibacterial peptide, having improved it becomes the development potentiality of antibiotic substitute.
Oral Pharmacokinetics

Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range. Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes.
<P>PROBLEM TO BE SOLVED: To provide a massage cream having a medical effect.  <P>SOLUTION: The massage cream includes a powder of a radioactive substance having an activity of 5.0-300.0 Bq. Preferably, the radioactive substance is thorium with 4.0-240.0 Bq, or uranium with 1.0-60.0 Bq. The massage cream is applied on the body of a person having massage. Massaging the person using a technique to rub the massage cream into the lymphatic vessels improves functions of the person such as cell repair function, cell activation function, and hormone balance improvement function.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Background and Objectives: The influence of montelukast (MK), an antagonist of cysLT1 leukotriene receptors, on lung lesions caused by experimental diabetes was studied. Materials and Methods: The study was conducted on four groups of six adult male Wistar rats. Diabetes was produced by administration of streptozotocin 65 mg/kg ip. in a single dose. Before the administration of streptozotocin, after 72 h, and after 8 weeks, the serum values of glucose, SOD, MDA, and total antioxidant capacity (TAS) were determined. After 8 weeks, the animals were anesthetized and sacrificed, and the lungs were harvested and examined by optical microscopy. Pulmonary fibrosis, the extent of lung lesions, and the lung wet-weight/dry-weight ratio were evaluated. Results: The obtained results showed that MK significantly reduced pulmonary fibrosis (3.34 ± 0.41 in the STZ group vs. 1.73 ± 0.24 in the STZ+MK group p < 0.01) and lung lesion scores and also decreased the lung wet-weight/dry-weight (W/D) ratio. SOD and TAS values increased significantly when MK was administered to animals with diabetes (77.2 ± 11 U/mL in the STZ group vs. 95.7 ± 13.3 U/mL in the STZ+MK group, p < 0.05, and 25.52 ± 2.09 Trolox units in the STZ group vs. 33.29 ± 1.64 Trolox units in the STZ+MK group, respectively, p < 0.01), and MDA values decreased. MK administered alone did not significantly alter any of these parameters in normal animals. Conclusions: The obtained data showed that by blocking the action of peptide leukotrienes on cysLT1 receptors, montelukast significantly reduced the lung lesions caused by diabetes. The involvement of these leukotrienes in the pathogenesis of fibrosis and other lung diabetic lesions was also demonstrated.
Many people cover their grey hair and silver hair by dyeing, as they are getting older and older, and they regularly dye their hair. Also, I am one of the people who think that dye is necessary, but I want to avoid the process of the dye and all processes related to dye like scalp stimulation occurrence, strong smell and hair loss whenever I dye. Fear and worries of dyeing other people make me try to develop a mordant for dyeing hair with various materials. After all, an edible mordant harmless to a human body is developed by using henna as coloring. (My opinion: the mordant of the present invention let me relieve stress out from dye and enjoy dyeing. In addition, frequent dyeing grey hair or silver hair is no longer damaging to hair or scalp. Many people tell me my smooth hair makes me younger).